Trevena Initiates Clinical Development of TRV734, a Novel Biased Ligand for Moderate to Severe Pain Feb 5, 2014 7:00 am EST
Trevena Announces Pricing of Initial Public Offering of 9,250,000 Shares of Common Stock Jan 31, 2014 6:30 am EST
Trevena Announces Dosing of First Patient in Phase 2b BLAST-AHF Trial of TRV027 for Acute Heart Failure Jan 9, 2014 7:00 am EST
First Clinical Experience of Trevena's lead CNS Biased Ligand, TRV130, Published in Journal of Clinical Pharmacology Oct 15, 2013 8:00 am EDT